| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 144 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027 |
| 08 Oct 2026 | SCHEDULE 13G/A |
| 06 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
THIRD AMENDED AND RESTATED BY-LAWS of VTV THERAPEUTICS INC. (A Delaware Corporation) TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 STOCKHOLDERS 3 ARTICLE 3 DIRECTORS 9 ARTICLE 4 COMMITTEES OF THE BOARD 15 ARTICLE 5 OFFICERS 15... |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 |
| 29 Jul 2026 | SCHEDULE 13G/A |
| 29 Jun 2026 |
Form 4: Baker Bros. Advisors Lp, Director and 5 others
Granted 12,000 Non-Qualified Stock Option (right to buy) |
| 29 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 26, 2026, vTv Therapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below: |
| 29 Jun 2026 |
Form 4: Spiegelman Daniel K, Director
Granted 6,000 Director stock option (right to buy) ($210K) |
| 29 Jun 2026 |
Form 4: Akkaraju Srinivas, Director
Granted 6,000 Director stock option (right to buy) ($210K) |
| 29 Jun 2026 |
Form 4: Al-Marzooqi Fahed, Director
Granted 6,000 Director stock option (right to buy) ($210K) |
| 29 Jun 2026 |
Form 4: Phillips Anne M., Director
Granted 6,000 Director stock option (right to buy) ($210K) |
| 10 Jun 2026 | DEFA14A |
| 13 May 2026 | 424B2 |
| 13 May 2026 |
8-K: Other Events
We have acted as special counsel to vTv Therapeutics Inc., a Delaware corporation (the “Company”), in connection with the sale from time to time of shares of the Company’s Class A common stock, par value $0.01 per share, having an aggreg... |
| 13 May 2026 | S-8 |
| 13 May 2026 | 10-Q |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 |
Loading...